-
Something wrong with this record ?
Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease
O. Mayer, J. Seidlerová, J. Bruthans, J. Filipovský, K. Timoracká, J. Vaněk, L. Cerná, P. Wohlfahrt, R. Cífková, E. Theuwissen, C. Vermeer,
Language English Country Ireland
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12102
MZ0
CEP Register
NT13186
MZ0
CEP Register
- MeSH
- Biomarkers blood MeSH
- Stroke blood mortality MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Extracellular Matrix Proteins blood chemistry MeSH
- Myocardial Infarction blood mortality MeSH
- Myocardial Ischemia blood mortality MeSH
- Kaplan-Meier Estimate MeSH
- Cardiovascular Diseases blood diagnosis MeSH
- Middle Aged MeSH
- Humans MeSH
- Vascular Diseases blood mortality MeSH
- Proportional Hazards Models MeSH
- Prospective Studies MeSH
- Calcium-Binding Proteins blood chemistry MeSH
- Regression Analysis MeSH
- Myocardial Revascularization mortality MeSH
- Aged MeSH
- Vitamin K metabolism MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Vitamin K is the essential co-factor for activation of matrix Gla-protein (MGP), the natural inhibitor of tissue calcification. Biologically inactive, desphospho-uncarboxylated MGP (dp-ucMGP) is a marker of vascular vitamin K status and is described to predict mortality in patients with heart failure and aortic stenosis. We hypothesized that increased dp-ucMGP might be associated with mortality risk in clinically stable patients with chronic vascular disease. MATERIALS AND METHODS: We examined 799 patients (mean age 65.1 ± 9.3 years) who suffered from myocardial infarction, coronary revascularization or first ischemic stroke (pooled Czech samples of EUROASPIRE III and EUROASPIRE-stroke surveys), and followed them in a prospective cohort study. To estimate the 5-year all-cause and cardiovascular mortality we ascertained vital status and declared cause of death. Circulating dp-ucMGP and desphospho-carboxylated MGP (dp-cMGP) were measured by ELISA methods (IDS and VitaK). RESULTS: During a median follow-up of 2050 days (5.6 years) 159 patients died. In the fully adjusted multivariate Cox proportional hazard model, the patients in the highest quartile of dp-ucMGP (≥ 977 pmol/L) had higher risk of all-cause and cardiovascular 5-year mortality [HRR 1.89 (95% CI, 1.32-2.72) and 1.88 (95% CI, 1.22-2.90)], respectively. Corresponding HRR for dp-cMGP were 1.76 (95% CI, 1.18-2.61) and 1.79 (95% CI, 1.12-2.57). CONCLUSIONS: In patients with overt vascular disease, circulating dp-ucMGP and dp-cMGP were independently associated with the risk of all-cause and cardiovascular mortality. Since published results are conflicting regarding the dp-cMGP, we propose only circulating dp-ucMGP as a potential biomarker for assessment of additive cardiovascular risk.
Biomedical Center Medical Faculty of Charles University Pilsen Czech Republic
Department of Neurology University Hospital Pilsen Czech Republic
International Clinical Research Centre St Anne's University Hospital Brno Czech Republic
VitaK Cardiovascular Research Institute Maastricht Maastricht University The Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16021094
- 003
- CZ-PrNML
- 005
- 20170523161142.0
- 007
- ta
- 008
- 160722s2014 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.atherosclerosis.2014.04.027 $2 doi
- 024 7_
- $a 10.1016/j.atherosclerosis.2014.04.027 $2 doi
- 035 __
- $a (PubMed)24835435
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Mayer, Otto, $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. Electronic address: mayero@fnplzen.cz. $d 1969- $7 xx0053346
- 245 10
- $a Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease / $c O. Mayer, J. Seidlerová, J. Bruthans, J. Filipovský, K. Timoracká, J. Vaněk, L. Cerná, P. Wohlfahrt, R. Cífková, E. Theuwissen, C. Vermeer,
- 520 9_
- $a BACKGROUND: Vitamin K is the essential co-factor for activation of matrix Gla-protein (MGP), the natural inhibitor of tissue calcification. Biologically inactive, desphospho-uncarboxylated MGP (dp-ucMGP) is a marker of vascular vitamin K status and is described to predict mortality in patients with heart failure and aortic stenosis. We hypothesized that increased dp-ucMGP might be associated with mortality risk in clinically stable patients with chronic vascular disease. MATERIALS AND METHODS: We examined 799 patients (mean age 65.1 ± 9.3 years) who suffered from myocardial infarction, coronary revascularization or first ischemic stroke (pooled Czech samples of EUROASPIRE III and EUROASPIRE-stroke surveys), and followed them in a prospective cohort study. To estimate the 5-year all-cause and cardiovascular mortality we ascertained vital status and declared cause of death. Circulating dp-ucMGP and desphospho-carboxylated MGP (dp-cMGP) were measured by ELISA methods (IDS and VitaK). RESULTS: During a median follow-up of 2050 days (5.6 years) 159 patients died. In the fully adjusted multivariate Cox proportional hazard model, the patients in the highest quartile of dp-ucMGP (≥ 977 pmol/L) had higher risk of all-cause and cardiovascular 5-year mortality [HRR 1.89 (95% CI, 1.32-2.72) and 1.88 (95% CI, 1.22-2.90)], respectively. Corresponding HRR for dp-cMGP were 1.76 (95% CI, 1.18-2.61) and 1.79 (95% CI, 1.12-2.57). CONCLUSIONS: In patients with overt vascular disease, circulating dp-ucMGP and dp-cMGP were independently associated with the risk of all-cause and cardiovascular mortality. Since published results are conflicting regarding the dp-cMGP, we propose only circulating dp-ucMGP as a potential biomarker for assessment of additive cardiovascular risk.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a proteiny vázající vápník $x krev $x chemie $7 D002135
- 650 _2
- $a kardiovaskulární nemoci $x krev $x diagnóza $7 D002318
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a extracelulární matrix - proteiny $x krev $x chemie $7 D016326
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a infarkt myokardu $x krev $x mortalita $7 D009203
- 650 _2
- $a ischemická choroba srdeční $x krev $x mortalita $7 D017202
- 650 _2
- $a revaskularizace myokardu $x mortalita $7 D009204
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a regresní analýza $7 D012044
- 650 _2
- $a cévní mozková příhoda $x krev $x mortalita $7 D020521
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nemoci cév $x krev $x mortalita $7 D014652
- 650 _2
- $a vitamin K $x metabolismus $7 D014812
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mlíková Seidlerová, Jitka, $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. $d 1977- $7 xx0096735
- 700 1_
- $a Bruthans, Jan, $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Centre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. $d 1948- $7 jn20000810219
- 700 1_
- $a Filipovský, Jan, $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. $d 1958- $7 xx0058293
- 700 1_
- $a Timoracká, Katarína $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic. $7 _AN080339
- 700 1_
- $a Vaněk, Jiří $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic. $7 xx0273624
- 700 1_
- $a Černá, Lenka $u Department of Neurology, University Hospital, Pilsen, Czech Republic. $7 xx0258278
- 700 1_
- $a Wohlfahrt, Peter $u Centre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; International Clinical Research Centre, St. Anne's University Hospital Brno, Czech Republic. $7 xx0230851
- 700 1_
- $a Cífková, Renata, $u Centre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; International Clinical Research Centre, St. Anne's University Hospital Brno, Czech Republic. $d 1955- $7 nlk20010094490
- 700 1_
- $a Theuwissen, Elke $u VitaK, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands.
- 700 1_
- $a Vermeer, Cees $u VitaK, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands.
- 773 0_
- $w MED00009284 $t Atherosclerosis $x 1879-1484 $g Roč. 235, č. 1 (2014), s. 162-168
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24835435 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20170523161538 $b ABA008
- 999 __
- $a ok $b bmc $g 1155764 $s 945622
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 235 $c 1 $d 162-168 $e 20140506 $i 1879-1484 $m Atherosclerosis $n Atherosclerosis $x MED00009284
- GRA __
- $a NT12102 $p MZ0
- GRA __
- $a NT13186 $p MZ0
- LZP __
- $a Pubmed-20160722
